<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1006">
  <stage>Registered</stage>
  <submitdate>6/12/2005</submitdate>
  <approvaldate>6/12/2005</approvaldate>
  <nctid>NCT00262717</nctid>
  <trial_identification>
    <studytitle>Can Resistance Enhance Selection of Treatment? (CREST)</studytitle>
    <scientifictitle>A Randomised Comparator Study to Assess the Relative Efficacy of Genotypic Versus Virtual Phenotypic Resistance Tests in Treatment Experienced Patients With HIV Infection for Whom a Change in Therapy is Indicated</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ACTR012605000781640</secondaryid>
    <secondaryid>TVRP9901</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>HIV Infection</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - HIV drug resistance tests based upon genotype testing

Treatment: devices: HIV drug resistance tests based upon genotype testing


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The comparison between randomly assigned study arms in the mean area under the curve plasma HIV RNA at 48 weeks.</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of patients with undetectable plasma HIV RNA, Changes in CD4+ cell count, use of resistance test result in selecting new ART regimen</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  HIV infected patients taking combination antiretroviral therapy, with plasma HIV RNA&gt;
             2000copies/mL, who were willing to change ARVs and who provided informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patients who were ARV na√Øve, who were experiencing an acute illness or judged to be
             unable to comply with the protocol requirements.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2001</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>ACT,NSW,QLD,SA,VIC,WA</recruitmentstate>
    <hospital>Interchange General Practice - Canberra</hospital>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <hospital>Sydney Sexual Health Clinic - Sydney</hospital>
    <hospital>AIDS Research Initiative - Sydney</hospital>
    <hospital>Albion Street Centre - Sydney</hospital>
    <hospital>Holdsworth House General Practice - Sydney</hospital>
    <hospital>St. Vincent's Hospital - Sydney</hospital>
    <hospital>Taylor Square Private Clinic - Sydney</hospital>
    <hospital>Prince of Wales Hospital - Sydney</hospital>
    <hospital>Livingston Road Sexual Health - Sydney</hospital>
    <hospital>QLD Health - AIDS Medical Unit - Brisbane</hospital>
    <hospital>Cairns Base Hospital - Cairns</hospital>
    <hospital>Gold Coast Sexual Health Clinic - Miami</hospital>
    <hospital>Care and Prevention Programme - Adelaide</hospital>
    <hospital>Alfred Hospital - Melbourne</hospital>
    <hospital>Melbourne Sexual Health Centre - Melbourne</hospital>
    <hospital>Prahran Market Clinic - Melbourne</hospital>
    <hospital>Fremantle Hospital - Fremantle</hospital>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <postcode> - Canberra</postcode>
    <postcode>2050 - Camperdown</postcode>
    <postcode>2000 - Sydney</postcode>
    <postcode>2010 - Sydney</postcode>
    <postcode>2031 - Sydney</postcode>
    <postcode> - Sydney</postcode>
    <postcode>4002 - Brisbane</postcode>
    <postcode>4870 - Cairns</postcode>
    <postcode>4220 - Miami</postcode>
    <postcode> - Adelaide</postcode>
    <postcode>3004 - Melbourne</postcode>
    <postcode>3053 - Melbourne</postcode>
    <postcode>3141 - Melbourne</postcode>
    <postcode>6160 - Fremantle</postcode>
    <postcode>6000 - Perth</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Kirby Institute</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Abbott</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Boehringer Ingelheim</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>GlaxoSmithKline</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Bristol-Myers Squibb</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Merck Sharp &amp; Dohme Corp.</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Roche Pharma AG</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Virco</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Diagnostic Technology</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Perkin Elmer Inc.</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To compare two commercially available platforms for assessment of HIV drug resistance to
      determine which provides superior virological results.

      We hypothesise that one test will be significantly superior to the other.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00262717</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Sean Emery, PhD</name>
      <address>The National Centre in HIV Epidemiology and Clinical Research at the University of New South Wales</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>